1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Leveraging New Approach Methodologies and Non-Animal Technologies to Accelerate Osteoarthritis Research is sponsored by National Institutes of Health (NIH) / National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This grant invites research applications utilizing New Approach Methodologies (NAMs) and Non-Animal Technologies (NATs), such as archived human joint tissues, organoids, tissue chips, advanced in vitro systems, computational and mathematical models, and non-invasive imaging techniques to investigate biological mechanisms driving osteoarthritis.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Investigator-initiated applications are considered. Confirm the full requirements in the official notice before applying.
Applications for Leveraging New Approach Methodologies and Non-Animal Technologies to Accelerate Osteoarthritis Research are due August 29, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Leveraging New Approach Methodologies and Non-Animal Technologies to Accelerate Osteoarthritis Research is funded by National Institutes of Health (NIH) / National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Supporting Research Using the Resources from the Osteoarthritis Initiative (OAI) is sponsored by National Institutes of Health (NIH) / National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This opportunity invites research grant applications focused on utilizing the Osteoarthritis Initiative (OAI) database, clinical data, and images. It aims to expand the use of these resources for novel analyses, exploration of OA epidemiology and progression, and application of new technologies to biospecimens and genetic data. Topics include the use of biospecimens to discover biochemical markers for early or progressive disease, integration of biospecimens with imaging and clinical data, and development of robust tools for automated image analysis for OA diagnosis and monitoring.
Clinical Investigator Award (K08) and Mentored Patient-Oriented Research Career Development Award (K23) is sponsored by National Institutes of Health (NIH) / National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). These career development awards are designed for clinicians who have a doctoral degree and are committed to a career in patient-oriented research. NIAMS supports training for basic and clinical scientists to carry out research into arthritis and musculoskeletal diseases.
Career Transition Award (K99/R00) is sponsored by National Institutes of Health (NIH) / National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This award is designed to facilitate the transition of outstanding postdoctoral researchers from mentored research positions to independent research careers. It combines a mentored (K99) and an independent (R00) phase.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article